CSM business likely to drive overall growth ahead The company launched four molecules last year, while it had around 25 molecules under the CSM portfolio earlier. The order backlog remains at around $ 1.5 billion, of which around 65-70% constitutes long term contracts while the rest are from a short-term contract. Going ahead, there are around 5-6 molecules at various stages of development, which is expected to be commercialised, going ahead. This would expand CSM portfolio and thereby the order backlog. Going ahead, since the new MPP is expected to...